Ozempic
4 comparisons available
About Ozempic
Ozempic (semaglutide) is a once-weekly injectable medication developed by Novo Nordisk, FDA-approved in 2017 for the treatment of type 2 diabetes. Its active ingredient, semaglutide, is a GLP-1 receptor agonist that works by stimulating insulin secretion, reducing glucagon production, and significantly decreasing appetite by slowing gastric emptying and acting on brain satiety centers. While Ozempic is approved for diabetes management, it has gained massive attention for its off-label use in weight loss — clinical trials show average body weight reductions of 14-15% over 68 weeks. Novo Nordisk launched Wegovy (a higher-dose version of semaglutide, 2.4mg vs Ozempic's 1mg) specifically for chronic weight management in 2021. Ozempic also demonstrated cardiovascular benefits, reducing the risk of major adverse cardiac events by 26% in the SUSTAIN-6 trial. The medication costs approximately $900-$1,000/month without insurance. Demand for Ozempic and Wegovy led to global supply shortages that persisted through 2024. Combined, Ozempic and Wegovy generated over $21 billion in revenue for Novo Nordisk in 2024.
Frequently Asked Questions
What is the difference between Ozempic and Wegovy?
Ozempic and Wegovy contain the same active ingredient (semaglutide) but are FDA-approved for different purposes. Ozempic (0.5mg-1mg dose) is approved for type 2 diabetes management. Wegovy (2.4mg dose) is approved for chronic weight management in adults with obesity or overweight with a weight-related condition. Wegovy's higher dose produces greater average weight loss (~15% vs ~10-12% for Ozempic's diabetes doses).
How much does Ozempic cost?
Ozempic costs approximately $900-$1,000/month (about $11,000/year) without insurance. Most commercial insurance plans cover Ozempic for type 2 diabetes. Novo Nordisk's savings card can reduce cost to $25/month for eligible commercially insured patients. Medicare Part D typically covers Ozempic for diabetes but not for weight loss.
Is Ozempic safe for weight loss?
Ozempic is FDA-approved for type 2 diabetes, not weight loss — prescribing it for weight loss is off-label. Wegovy (same molecule, higher dose) is approved for weight loss. Common side effects include nausea, vomiting, and diarrhea. Serious risks include pancreatitis, gallbladder disease, and a potential (theoretical in humans) risk of thyroid tumors. Always consult a physician before starting GLP-1 medications.
Top Alternatives to Ozempic
Wegovy
Higher-dose semaglutide specifically approved for weight loss
Mounjaro
Tirzepatide (dual GIP/GLP-1), Eli Lilly, potentially greater weight loss
Zepbound
Tirzepatide approved specifically for weight loss (Eli Lilly)
Rybelsus
Oral semaglutide (same molecule as Ozempic, taken by mouth)
Victoza
Older GLP-1 (liraglutide), daily injection, well-established
Saxenda
Liraglutide weight-loss version, daily injection